Table 1.
Clinical details of MS patients and control subjects
| A. Tissues used for RT-PCR analysis | |||||
| Donor | Age | Gender | PM delay (h:m) | Diagnosis | Cause of death |
| 1 | 51 | M | 7.30 | CON | Euthanasia; esophageal cancer |
| 2 | 56 | M | 9.15 | CON | Myocardial infarction |
| 3 | 62 | M | 7.20 | CON | Unknown |
| 4 | 66 | F | 6.00 | MS (N/A) | Unknown |
| 5 | 61 | M | 9.15 | MS (SP) | Euthanasia |
| 6 | 50 | F | 7.35 | MS (SP) | Euthanasia |
| 7 | 66 | F | 9.35 | MS (PP) | Euthanasia |
| B. Tissues used for immunohistochemical studies | |||||
| 1 | 51 | M | 7.30 | CON | Euthanasia; esophageal carcinoma |
| 2 | 56 | M | 9.15 | CON | Myocardial infarction |
| 5 | 61 | M | 9.15 | MS (SP) | Euthanasia |
| 6 | 50 | F | 7.35 | MS (SP) | Euthanasia |
| 7 | 66 | F | 9.35 | MS (PP) | Euthanasia |
| 8 | 82 | M | 6.53 | CON | Pleuritis carcinomatosis |
| 9 | 87 | M | 6.32 | CON | Pneumonia |
| 10 | 66 | M | 7.45 | CON | Ruptured abdominal aorta aneurysm |
| 11 | 88 | M | 7.00 | CON | End stage rectum and prostate carcinoma |
| 12 | 60 | F | 7.30 | CON | Infection e.c.i |
| 13 | 51 | M | 7.45 | CON | Suicide |
| 14 | 41 | F | 8.25 | MS (SP) | Unknown |
| 15 | 43 | F | 10.45 | MS (SP) | Subdural haematoma, pneumonia |
| 16 | 56 | M | 8.00 | MS (SP) | Pneumonia |
| 17 | 78 | F | 11.10 | MS (N/A) | Cerebrovascular accident |
| 18 | 66 | M | 7.30 | MS (PP) | Ileus |
| 19 | 77 | F | 10.00 | MS (SP) | Euthanasia |
| 20 | 45 | M | 7.45 | MS (N/A) | Pulmonary embolism |
| 21 | 83 | M | 7.50 | MS (PP) | Aspiration pneumonia |
| 22 | 74 | M | 10.15 | MS (N/A) | Cardio-respiratory insufficiency |
| 23 | 54 | M | 8.15 | MS (PP) | Euthanasia |
| 24 | 53 | M | 10.00 | MS (SP) | Euthanasia |
| 25 | 56 | F | 8.25 | MS (SP) | Pneumonia |
| 26 | 54 | M | 10.50 | MS (N/A) | Euthanasia |
| 27 | 87 | F | 9.30 | MS (N/A) | Renal insufficiency |
PM post mortem, M male, F female, CON control, MS multiple sclerosis, SP secondary progressive, PP primary progressive, N/A not known